They approach to accomplish this 2nd stage III study by the tip of the 12 months. Once the section III is comprehensive, MAPS will apply for FDA approval for MDMA therapy. They foresee FDA approval to come in late 2023. As soon as it is actually authorized, the DEA may have 3 months to re-plan or de-program MDMA from its existing Plan-1 status. MAP